ACBM at a glance
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
ACBM price history
Loading ACBM and S&P 500 price history…
Loading recent earnings…
Investment thesis
What must happen next
External funding is the gating input for any business restart because Acro has no self-funding operating base and says it needs significant funding to implement its preliminary business plan.StrengtheningMateriality: High
GAAP cash was only $4,098 at December 31, 2025, despite the company needing funds to recommence operations. If funding arrives on workable terms, ACBM has a chance to buy inventory and resume marketing; if it does not, the operating story cannot restart.
Watch: A binding non-dilutive loan facility or customer prepayment large enough to fund inventory purchases and marketing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP cash was only $4,098 at December 31, 2025, despite the company needing funds to recommence operations.
Open source ↗The prior demand channel has to be rebuilt, not merely reactivated, because historical sales were concentrated in a few customers and all sales were made by one part-time CEO who has resigned.WeakeningMateriality: High
GAAP annual revenue was $0 in FY2023, $0 in FY2024, and $0 in FY2025. A restart requires new paying customers and a sales function; otherwise revenue remains an artifact of old relationships rather than a repeatable business.
Watch: A signed purchase order from a new unrelated customer for cordyceps or complementary wellness products.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $0 in FY2023, $0 in FY2024, and $0 in FY2025.
Open source ↗Durable value requires Acro to secure differentiated products, exclusive supply, or proprietary development, because the current described model is mainly resale of supplier-sourced cordyceps products with no proven pricing power.HoldingMateriality: Medium
GAAP annual gross profit was $259,500 in FY2021 and $140,500 in FY2022, then $0 in FY2023 after sales stopped. If Acro remains an undifferentiated reseller, any sales revival could carry weak margins and little defensible value; differentiation would make the restart more investable.
Watch: An exclusive supplier agreement for cordyceps or another wellness product that gives Acro protected distribution economics.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit was $259,500 in FY2021 and $140,500 in FY2022, then $0 in FY2023 after sales stopped.
Open source ↗Any commercial restart is likely to be constrained by dilution risk because Acro has negative book equity, limited cash, no active public quotation, and says equity financing may be difficult and dilutive.StrengtheningMateriality: Medium
GAAP stockholders’ equity was negative $386,964 at December 31, 2025. Even a successful operating restart may not create per-share value if the capital required to restart the business is raised on punitive terms.
Watch: A non-dilutive financing package or customer-funded working-capital arrangement.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP stockholders’ equity was negative $386,964 at December 31, 2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
External funding is the gating input for any business restart because Acro has no self-funding operating base and says it needs significant funding to implement its preliminary business plan. If funding arrives on workable terms, ACBM has a chance to buy inventory and resume marketing; if it does not, the operating story cannot restart.
The prior demand channel has to be rebuilt, not merely reactivated, because historical sales were concentrated in a few customers and all sales were made by one part-time CEO who has resigned. A restart requires new paying customers and a sales function; otherwise revenue remains an artifact of old relationships rather than a repeatable business.
Durable value requires Acro to secure differentiated products, exclusive supply, or proprietary development, because the current described model is mainly resale of supplier-sourced cordyceps products with no proven pricing power. If Acro remains an undifferentiated reseller, any sales revival could carry weak margins and little defensible value; differentiation would make the restart more investable.
Any commercial restart is likely to be constrained by dilution risk because Acro has negative book equity, limited cash, no active public quotation, and says equity financing may be difficult and dilutive. Even a successful operating restart may not create per-share value if the capital required to restart the business is raised on punitive terms.
All standing thesis claims
Original report summary
ACBM is not a durable operating compounder today; it is a financed-restart option on a dormant cordyceps/wellness distributor whose core problems are customers, suppliers, leadership, and cash.
Bull case and bear case
Bull case and bear case for Acro Biomedical Co.
Where the evidence on Acro Biomedical Co. disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
External funding is the gating input for any business restart because Acro has no self-funding operating base and says it needs significant funding to implement its preliminary business plan.
Durable value requires Acro to secure differentiated products, exclusive supply, or proprietary development, because the current described model is mainly resale of supplier-sourced cordyceps products with no proven pricing power.
Any commercial restart is likely to be constrained by dilution risk because Acro has negative book equity, limited cash, no active public quotation, and says equity financing may be difficult and dilutive.
Bear case: what the evidence questions
The prior demand channel has to be rebuilt, not merely reactivated, because historical sales were concentrated in a few customers and all sales were made by one part-time CEO who has resigned.
Thesis-Break Engine
What has broken in Acro Biomedical Co.’s thesis
Each break OptimistFi flagged on Acro Biomedical Co., dated — with what has historically followed the same kind of break across the market, not a forecast for Acro Biomedical Co..
- Late SEC filingcondition set before this filing
Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.
- CEO / officer changecondition set before this filing
Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Acro Biomedical Co.’s latest quarterly report, ahead of the annual figure it is written on.
- Revenue decline, trailing 12 months
Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.
Several kinds of break have stacked on Acro Biomedical Co. at once. A cluster is a stronger read than any one signal alone.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDirector or principal officer change.
Acro Biomedical Co. filed an SEC 8-K on 2026-09-02: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A binding non-dilutive loan facility or customer prepayment large enough to fund inventory purchases and marketing.
- A signed purchase order from a new unrelated customer for cordyceps or complementary wellness products.
- An exclusive supplier agreement for cordyceps or another wellness product that gives Acro protected distribution economics.
- A non-dilutive financing package or customer-funded working-capital arrangement.
ACBM news
Loading headlines…
Financial statements
ACBM income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

